Every Form 4 that Delcath Sys (DCTH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DCTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DCTH filings page.
DELCATH SYSTEMS, INC. director John Richard Sylvester received a grant of stock options for 22,500 shares of common stock at an exercise price of $11.61 per share. The options vest in equal monthly installments, with one-twelfth vesting each month starting on May 13, 2026, as long as he remains a director. Any vested options expire the earlier of 10 years from the grant date or two years after his last day of service.
DELCATH SYSTEMS, INC. director Bridget A. Martell received a grant of stock options as equity compensation. The award covers 22,500 options for common stock at an exercise price of $11.61 per share, and she now holds 22,500 options following this grant.
These options vest in equal monthly installments of one-twelfth, starting on May 13, 2026, as long as she continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire on the earlier of 10 years from grant or two years after her service ends for vested portions.
DELCATH SYSTEMS, INC. director Elizabeth Czerepak received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and are compensation rather than an open-market purchase.
The award vests at a rate of one-twelfth per month, with the first vesting on May 13, 2026 and monthly thereafter while she remains a director under the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from the grant date or two years after her service ends.
DELCATH SYSTEMS, INC. director Steven A. J. Salamon received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and represent a compensation-related award, not an open-market purchase.
The options vest in equal monthly installments of one-twelfth of the grant, starting on May 13, 2026, as long as he continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire 10 years from the grant date or, for vested portions, two years after his last day of service.
DELCATH SYSTEMS, INC. director Aharon Gil received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and were awarded as compensation, not through an open-market purchase or sale.
The grant vests in equal monthly installments of one-twelfth of the total, starting on May 13, 2026, so long as Gil remains a director and subject to the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from grant or two years after service ends.
DELCATH SYSTEMS, INC. Chief Financial Officer Sandra Pennell reported an open-market purchase of common stock. She bought 5,533 shares of Delcath Systems common stock at a price of $9.04 per share. Following this transaction, she directly owned a total of 77,018 common shares, which includes 10,433 shares acquired under the company’s 2021 Employee Stock Purchase Plan.
DELCATH SYSTEMS, INC. chief executive officer Michel Gerard purchased 11,200 shares of common stock in an open-market transaction. The shares were bought at an average price of $8.9562 per share and are held directly. After this purchase, he owns 342,034 common shares.
Hoffman David L. reported acquisition or exercise transactions in this Form 4 filing.
Delcath Systems, Inc. reported that its General Counsel, Chief Compliance Officer and Secretary, David L. Hoffman, received equity awards under the company’s 2020 Omnibus Equity Incentive Plan. He was granted stock options for 56,500 shares at no cost and 28,250 restricted stock units, each representing one share of common stock.
The option award vests in equal monthly installments over 36 months, beginning on February 17, 2026, as long as he remains an employee. The RSU award vests over three years, with one-third vesting on February 17, 2027 and the remaining two-thirds vesting in equal annual installments over the next two years, contingent on continued service.
Delcath Systems, Inc. granted equity awards to Kevin Muir, its GM Interventional Oncology. On February 17, 2026, he acquired a stock option covering 56,500 shares at an exercise price of $0.00 per share, vesting in equal monthly installments over 36 months, starting February 17, 2026, while he remains an employee and subject to the company’s 2020 Omnibus Equity Incentive Plan.
On the same date, he also received 28,250 restricted stock units (RSUs), each representing a contingent right to one share of common stock. One-third of this RSU award will vest on February 17, 2027, with the remaining two-thirds vesting in equal annual installments over the following two years, subject to his continuous service through each vesting date.
Pennell Sandra reported acquisition or exercise transactions in this Form 4 filing.
Delcath Systems Chief Financial Officer Sandra Pennell reported equity awards that increase her potential ownership stake over time. She was granted stock options for 56,500 shares at no cost, which vest monthly in equal installments over 36 months starting on February 17, 2026, as long as she remains an employee.
She also received 28,250 restricted stock units, each representing a right to one share of common stock. One-third of these RSUs will vest on February 17, 2027, with the remaining two-thirds vesting in equal annual installments over the following two years, subject to her continued service.
Delcath Systems chief medical officer Vojo Vukovic received new equity awards. On February 17, 2026, he was granted stock options for 56,500 shares at an exercise price of $0.00 per share and 28,250 restricted stock units (RSUs).
The options vest at a rate of one‑thirty‑sixth per month starting on February 17, 2026, as long as he remains an employee under the company’s 2020 Omnibus Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock, with one‑third vesting on February 17, 2027 and the remaining two‑thirds in equal annual installments over the following two years, subject to continued service.
Rook Martha S. reported acquisition or exercise transactions in this Form 4 filing.
Delcath Systems chief operating officer Martha S. Rook reported new equity compensation grants. She received stock options for 56,500 shares at no cost, vesting at a rate of one‑thirty‑sixth per month starting on February 17, 2026, as long as she remains an employee.
Rook also received 28,250 restricted stock units, each representing one share of common stock. One‑third of these RSUs will vest on February 17, 2027, with the remaining two‑thirds vesting in equal annual installments over the following two years, subject to her continuous service.
Delcath Systems, Inc. reported that Chief Executive Officer Michel Gerard J acquired equity awards consisting of stock options and restricted stock units. He received stock options for 195,000 shares at an exercise price of $0.0000 per share, classified as a grant or award acquisition.
The option vests at a rate of one‑thirty‑sixth per month starting on February 17, 2026, continuing monthly while he remains an employee under the company’s 2020 Omnibus Equity Incentive Plan. He was also granted 97,500 restricted stock units, each representing a contingent right to one share of common stock.
One‑third of the RSUs vest on February 17, 2027, with the remaining two‑thirds vesting in equal annual installments over the following two years, subject to his continuous service through each vesting date.
Delcath Systems, Inc. director reports open-market stock purchase. A company director bought 4,386 shares of Delcath Systems common stock on 11/21/2025 at a price of $8.89 per share in a transaction reported as a purchase. After this trade, the director beneficially owns 14,936 shares, held directly. The filing is a routine Form 4 disclosure showing insider ownership and the latest change in the director's personal investment in Delcath stock.
Delcath Systems (DCTH) reported an insider share purchase by its Chief Executive Officer and Director, Gerard Michel. On 11/11/2025, he purchased 11,500 shares of common stock at $8.526 per share, coded as “P,” indicating a purchase. Following this transaction, his beneficial ownership stands at 330,834 shares, held directly.